Cargando…

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer

Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chunmei, Liu, Min, Li, Yutao, Zhao, Yi, Sharma, Amit, Liu, Haotian, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346844/
https://www.ncbi.nlm.nih.gov/pubmed/37457699
http://dx.doi.org/10.3389/fimmu.2023.1213716
_version_ 1785073409390018560
author Hu, Chunmei
Liu, Min
Li, Yutao
Zhao, Yi
Sharma, Amit
Liu, Haotian
Schmidt-Wolf, Ingo G. H.
author_facet Hu, Chunmei
Liu, Min
Li, Yutao
Zhao, Yi
Sharma, Amit
Liu, Haotian
Schmidt-Wolf, Ingo G. H.
author_sort Hu, Chunmei
collection PubMed
description Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T cell immunotherapy has significantly transformed the therapeutic approaches for leukemia and lymphoma and has garnered increased attention as a potential treatment for a wide range of cancers. However, CAR-T immunotherapy in solid tumors, especially HNSCCs, lags significantly behind due to the paucity of tumor-specific antigens, high levels of tumor heterogeneity, immunosuppressive tumor microenvironment, the risk of treatment-related toxicities and off-target adverse events in HNSCCs. The objective of this review is to explore the advancement of CAR-T cell therapy in the treatment of HNSCCs. We aim to outline the targeted antigens in HNSCCs, highlight the challenges and potential solutions, and discuss the relevant combination therapies. Our review presents a comprehensive overview of the recent developments in CAR-T cell therapy for HNSCCs, and provides valuable insights into future research avenues.
format Online
Article
Text
id pubmed-10346844
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103468442023-07-15 Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer Hu, Chunmei Liu, Min Li, Yutao Zhao, Yi Sharma, Amit Liu, Haotian Schmidt-Wolf, Ingo G. H. Front Immunol Immunology Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T cell immunotherapy has significantly transformed the therapeutic approaches for leukemia and lymphoma and has garnered increased attention as a potential treatment for a wide range of cancers. However, CAR-T immunotherapy in solid tumors, especially HNSCCs, lags significantly behind due to the paucity of tumor-specific antigens, high levels of tumor heterogeneity, immunosuppressive tumor microenvironment, the risk of treatment-related toxicities and off-target adverse events in HNSCCs. The objective of this review is to explore the advancement of CAR-T cell therapy in the treatment of HNSCCs. We aim to outline the targeted antigens in HNSCCs, highlight the challenges and potential solutions, and discuss the relevant combination therapies. Our review presents a comprehensive overview of the recent developments in CAR-T cell therapy for HNSCCs, and provides valuable insights into future research avenues. Frontiers Media S.A. 2023-06-29 /pmc/articles/PMC10346844/ /pubmed/37457699 http://dx.doi.org/10.3389/fimmu.2023.1213716 Text en Copyright © 2023 Hu, Liu, Li, Zhao, Sharma, Liu and Schmidt-Wolf https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hu, Chunmei
Liu, Min
Li, Yutao
Zhao, Yi
Sharma, Amit
Liu, Haotian
Schmidt-Wolf, Ingo G. H.
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title_full Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title_fullStr Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title_full_unstemmed Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title_short Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
title_sort recent advances and future perspectives of car-t cell therapy in head and neck cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346844/
https://www.ncbi.nlm.nih.gov/pubmed/37457699
http://dx.doi.org/10.3389/fimmu.2023.1213716
work_keys_str_mv AT huchunmei recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT liumin recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT liyutao recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT zhaoyi recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT sharmaamit recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT liuhaotian recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer
AT schmidtwolfingogh recentadvancesandfutureperspectivesofcartcelltherapyinheadandneckcancer